Drug Trial Radar · NCT01339689
Ganaxolone in Posttraumatic Stress Disorder (PTSD)
Last checked: Nov 19, 2026Latest source record: Dec 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
112
Actual
Start
Apr 2011
Primary completion
Jan 2014
Study completion Mar 2014
Sponsor
- Lead sponsor
- Marinus PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium; U.S. Army Medical Research and Development Command
- First posted
- Apr 21, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2 proof-of-concept study is a double-blind, randomized, placebo-controlled, 15-week investigation of ganaxolone versus placebo for the treatment of Posttraumatic Stress Disorder (PTSD). Up to 120 participants will be enrolled and randomized to receive either ganaxolone or placebo for 6 weeks. After 6 weeks of randomized treatment all participants will continue for 6 weeks on ganaxolone. The aim of the study is to assess the efficacy of ganaxolone compared to placebo for the treatment of PTSD symptoms after 6 weeks of treatment using the Clinician-Administered PTSD Rating Scale (CAPS). The second aim of the study is to evaluate the safety and tolerability of ganaxolone in the PTSD population.
Conditions
- PTSD
Interventions
GanaxoloneDrug
200-600 mg bid, capsules, up to 12 weeks
PlaceboDrug
capsules, bid, up to 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Clinician-Administered Posttrautamtic Stress Disorder (PTSD) Scale (CAPS) to Week 6Time frame: Baseline (Week 0) and at Week 2, Week 4 and Week 6
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
VA San Diego Healthcare System/ University of California, San Diego
San Diego, California
Washington DC VA Medical Center/ Uniformed Services University of the Health Services
Washington D.C., District of Columbia
VA Boston Healthcare Services/ Spaulding Rehabilitation Hospital
Boston, Massachusetts
Manchester VA Medical Center/ Dartmouth College
Manchester, New Hampshire
Durham VA Medical Center /Duke University Medical Center
Durham, North Carolina
Cincinnati VA Medical Center/ University of Cincinnati
Cincinnati, Ohio
Charleston VA Medica Center/ Medical University of South Carolina
Charleston, South Carolina
White River Junction VA Medical Center/ Dartmouth College
White River Junction, Vermont
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.